Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F.
Romano A, et al.
Br J Haematol. 2019 May;185(3):468-479. doi: 10.1111/bjh.15801. Epub 2019 Feb 15.
Br J Haematol. 2019.
PMID: 30768678
Free article.
Clinical Trial.